The U.S. Food and Drug Administration on Thursday approved GlaxoSmithKline Plc’s HIV drug, Rukobia, to treat adult patients who have run out of treatment options.
Antiretroviral medicines suppress HIV and help in decreasing disease progression, HIV transmission, and AIDS-related deaths. However, HIV has the ability to constantly change and can lead to some individuals developing viral resistance, causing their treatment regimens to fail.
The most common adverse reactions from the drug, taken twice daily, were nausea, fatigue and diarrhea.
Pfizer and Shionogi & Co Ltd hold small stakes in ViiV Healthcare.
